{
    "info": {
        "nct_id": "NCT03073967",
        "official_title": "A Randomized, Open Label, Multi-center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir for the Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1)",
        "inclusion_criteria": "Part C inclusion criteria\n\n1. Immunocompromised men and women of any ethnic group aged ≥16 years.\n\n   In Canada, Germany, Belgium:\n\n   Immunocompromised (due to conditions including but not limited to HIV infection, hematopoietic cell or solid organ transplantation, and chronic use of immunosuppressive treatment) men and women of any ethnic group aged >18 years.\n2. ACV-R mucocutaneous HSV infection based on clinical failure or positive genotypic/phenotypic ACV resistance testing for current lesion. Clinical failure is defined as no improvement after oral or iv doses for at least 7 days at doses equivalent to or greater than the local agency approved high oral doses of acyclovir, valacyclovir or famciclovir.\n3. Lesions accessible for visual inspection to allow assessment of lesion healing including visualization by endoscopy.\n4. Willingness to use highly effective birth control.\n5. Subject, and/or their legally authorized representative, (proxy consent is not permitted in Germany), must be willing and able to understand the Informed Consent Form.\n6. Negative serum β-HCG (beta-human chorionic gonadotropin) test for women of child-bearing potential at Screening and a negative urine pregnancy test at Day 1.\n7. Written informed consent. For subjects, who are unable to provide informed consent for whatever reason, written consent must be obtained from the legal representative, (proxy consent is not permitted in Germany).\n\nPart D and F inclusion criteria\n\nAll inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by:\n\n2. ACV-R and foscarnet-R mucocutaneous HSV infection based on clinical failure or positive genotypic/phenotypic resistance testing for current lesion or documented intolerance to iv foscarnet requiring cessation of foscarnet treatment or precluding foscarnet treatment.\n\nSubjects will be able to enter Part F only after closure of enrollment in Part D.\n\nPart E inclusion (Part E is not being conducted in Germany)\n\nAll inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by:\n\n2. Recurrent mucocutaneous HSV infection considered ACV-S.\n\nPart C exclusion criteria\n\n1. Known resistance/intolerance to pritelivir or any of the excipients.\n2. Previous treatment in PRIOH-1.\n3. Baseline safety laboratory abnormalities.\n4. History or current evidence of gastrointestinal malabsorption which, in the opinion of the Investigator, may affect the extent of absorption of pritelivir.\n5. Hemodialysis for any indication and ESRD (eGFR <15 mL/min; stage 5 CKD)\n6. History or current evidence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrinological, metabolic, neurological, psychiatric, or other relevant diseases.\n7. Abnormalities in hematological, clinical chemical or any other laboratory variables.\n8. Not able to communicate meaningfully with the Investigator and site staff.\n9. Any other condition which in the opinion of the Investigator would interfere with successful completion of this clinical trial.\n10. Any other important local condition.\n11. Pregnant and/or breastfeeding women.\n12. Having received an investigational drug in an investigational drug trial unter certain conditions.\n\n    Part D (complete) exclusion criteria\n\n    All exclusion criteria as for Part C, except criterion 12, which is replaced by:\n13. Having received an investigational drug in an investigational trial within 7 half-lives after the last administration of this drug before initiating trial medication, except for subjects entering Part D, who have previously received foscarnet treatment in Part C of this trial.\n\nParticipation in a clinical trial without receiving other investigational drugs (eg, follow-up phase of a trial, observational study) is permitted.\n\nPart E exclusion criteria (Part E is not being conducted in Germany)\n\nAll exclusion criteria in Part E are identical to those in Part C with the addition of:\n\n13. Having used acyclovir, valacyclovir, or famciclovir within 3 days prior to starting pritelivir.\n\nPart F exclusion criteria All exclusion criteria for Part D plus 13. Part D open for enrollment\nHealthy volunteers allowed\nMust have minimum age of 16 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Part C inclusion criteria",
            "criterions": [
                {
                    "exact_snippets": "Part C inclusion criteria",
                    "criterion": "Part C inclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Baseline safety laboratory abnormalities.",
            "criterions": [
                {
                    "exact_snippets": "Baseline safety laboratory abnormalities",
                    "criterion": "safety laboratory abnormalities at baseline",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 16 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 16 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 16,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Part E exclusion criteria (Part E is not being conducted in Germany)",
            "criterions": [
                {
                    "exact_snippets": "Part E is not being conducted in Germany",
                    "criterion": "study site location",
                    "requirements": [
                        {
                            "requirement_type": "country",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "Germany"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Previous treatment in PRIOH-1.",
            "criterions": [
                {
                    "exact_snippets": "Previous treatment in PRIOH-1",
                    "criterion": "previous treatment in PRIOH-1",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Not able to communicate meaningfully with the Investigator and site staff.",
            "criterions": [
                {
                    "exact_snippets": "Not able to communicate meaningfully with the Investigator and site staff.",
                    "criterion": "ability to communicate meaningfully with the Investigator and site staff",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "All inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by:",
            "criterions": [
                {
                    "exact_snippets": "All inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by:",
                    "criterion": "inclusion criteria for Part C (except criterion 2)",
                    "requirements": [
                        {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Known resistance/intolerance to pritelivir or any of the excipients.",
            "criterions": [
                {
                    "exact_snippets": "Known resistance/intolerance to pritelivir",
                    "criterion": "resistance or intolerance to pritelivir",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known resistance/intolerance to ... any of the excipients",
                    "criterion": "resistance or intolerance to any of the excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. History or current evidence of gastrointestinal malabsorption which, in the opinion of the Investigator, may affect the extent of absorption of pritelivir.",
            "criterions": [
                {
                    "exact_snippets": "History or current evidence of gastrointestinal malabsorption",
                    "criterion": "gastrointestinal malabsorption",
                    "requirements": [
                        {
                            "requirement_type": "history or current evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "which, in the opinion of the Investigator, may affect the extent of absorption of pritelivir",
                    "criterion": "potential to affect pritelivir absorption",
                    "requirements": [
                        {
                            "requirement_type": "investigator opinion of effect on pritelivir absorption",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. History or current evidence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrinological, metabolic, neurological, psychiatric, or other relevant diseases.",
            "criterions": [
                {
                    "exact_snippets": "History or current evidence of significant cardiovascular ... diseases.",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "temporal",
                            "expected_value": [
                                "history",
                                "current evidence"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "History or current evidence of significant ... pulmonary ... diseases.",
                    "criterion": "pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "temporal",
                            "expected_value": [
                                "history",
                                "current evidence"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "History or current evidence of significant ... hepatic ... diseases.",
                    "criterion": "hepatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "temporal",
                            "expected_value": [
                                "history",
                                "current evidence"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "History or current evidence of significant ... renal ... diseases.",
                    "criterion": "renal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "temporal",
                            "expected_value": [
                                "history",
                                "current evidence"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "History or current evidence of significant ... gastrointestinal ... diseases.",
                    "criterion": "gastrointestinal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "temporal",
                            "expected_value": [
                                "history",
                                "current evidence"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "History or current evidence of significant ... hematological ... diseases.",
                    "criterion": "hematological disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "temporal",
                            "expected_value": [
                                "history",
                                "current evidence"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "History or current evidence of significant ... endocrinological ... diseases.",
                    "criterion": "endocrinological disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "temporal",
                            "expected_value": [
                                "history",
                                "current evidence"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "History or current evidence of significant ... metabolic ... diseases.",
                    "criterion": "metabolic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "temporal",
                            "expected_value": [
                                "history",
                                "current evidence"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "History or current evidence of significant ... neurological ... diseases.",
                    "criterion": "neurological disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "temporal",
                            "expected_value": [
                                "history",
                                "current evidence"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "History or current evidence of significant ... psychiatric ... diseases.",
                    "criterion": "psychiatric disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "temporal",
                            "expected_value": [
                                "history",
                                "current evidence"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "History or current evidence of significant ... other relevant diseases.",
                    "criterion": "other relevant disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "temporal",
                            "expected_value": [
                                "history",
                                "current evidence"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Negative serum β-HCG (beta-human chorionic gonadotropin) test for women of child-bearing potential at Screening and a negative urine pregnancy test at Day 1.",
            "criterions": [
                {
                    "exact_snippets": "Negative serum β-HCG (beta-human chorionic gonadotropin) test for women of child-bearing potential at Screening",
                    "criterion": "serum β-HCG test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "population",
                            "expected_value": "women of child-bearing potential"
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "Screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "a negative urine pregnancy test at Day 1",
                    "criterion": "urine pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "Day 1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Immunocompromised men and women of any ethnic group aged ≥16 years.",
            "criterions": [
                {
                    "exact_snippets": "Immunocompromised",
                    "criterion": "immunocompromised status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "men and women",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "any ethnic group",
                    "criterion": "ethnic group",
                    "requirements": [
                        {
                            "requirement_type": "allowed values",
                            "expected_value": "any"
                        }
                    ]
                },
                {
                    "exact_snippets": "aged ≥16 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 16,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Part C exclusion criteria",
            "criterions": [
                {
                    "exact_snippets": "Part C exclusion criteria",
                    "criterion": "Part C exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Participation in a clinical trial without receiving other investigational drugs (eg, follow-up phase of a trial, observational study) is permitted.",
            "criterions": [
                {
                    "exact_snippets": "Participation in a clinical trial without receiving other investigational drugs",
                    "criterion": "participation in a clinical trial",
                    "requirements": [
                        {
                            "requirement_type": "concurrent investigational drug use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Part D and F inclusion criteria",
            "criterions": [
                {
                    "exact_snippets": "Part D and F inclusion criteria",
                    "criterion": "inclusion in Part D and F",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": [
                                "Part D",
                                "Part F"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Recurrent mucocutaneous HSV infection considered ACV-S.",
            "criterions": [
                {
                    "exact_snippets": "Recurrent mucocutaneous HSV infection",
                    "criterion": "mucocutaneous HSV infection",
                    "requirements": [
                        {
                            "requirement_type": "recurrence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "considered ACV-S",
                    "criterion": "HSV infection acyclovir sensitivity",
                    "requirements": [
                        {
                            "requirement_type": "acyclovir sensitivity",
                            "expected_value": "sensitive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Part E inclusion (Part E is not being conducted in Germany)",
            "criterions": [
                {
                    "exact_snippets": "Part E inclusion",
                    "criterion": "Part E inclusion",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Part E is not being conducted in Germany",
                    "criterion": "study site location",
                    "requirements": [
                        {
                            "requirement_type": "country",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "Germany"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Any other important local condition.",
            "criterions": [
                {
                    "exact_snippets": "Any other important local condition",
                    "criterion": "local condition",
                    "requirements": [
                        {
                            "requirement_type": "importance",
                            "expected_value": "important"
                        }
                    ]
                }
            ]
        },
        {
            "line": "All exclusion criteria as for Part C, except criterion 12, which is replaced by:",
            "criterions": [
                {
                    "exact_snippets": "All exclusion criteria as for Part C, except criterion 12",
                    "criterion": "exclusion criteria for Part C (except criterion 12)",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Having used acyclovir, valacyclovir, or famciclovir within 3 days prior to starting pritelivir.",
            "criterions": [
                {
                    "exact_snippets": "Having used acyclovir, valacyclovir, or famciclovir within 3 days prior to starting pritelivir.",
                    "criterion": "use of acyclovir, valacyclovir, or famciclovir",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "days prior to starting pritelivir"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Hemodialysis for any indication and ESRD (eGFR <15 mL/min; stage 5 CKD)",
            "criterions": [
                {
                    "exact_snippets": "Hemodialysis for any indication",
                    "criterion": "hemodialysis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ESRD (eGFR <15 mL/min; stage 5 CKD)",
                    "criterion": "end-stage renal disease (ESRD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "eGFR <15 mL/min",
                    "criterion": "estimated glomerular filtration rate (eGFR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 15,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "stage 5 CKD",
                    "criterion": "chronic kidney disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "5"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Willingness to use highly effective birth control.",
            "criterions": [
                {
                    "exact_snippets": "Willingness to use highly effective birth control",
                    "criterion": "birth control usage",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": "highly effective"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Part F exclusion criteria All exclusion criteria for Part D plus 13. Part D open for enrollment",
            "criterions": [
                {
                    "exact_snippets": "All exclusion criteria for Part D",
                    "criterion": "Part D exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Part D open for enrollment",
                    "criterion": "Part D enrollment status",
                    "requirements": [
                        {
                            "requirement_type": "open for enrollment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Written informed consent. For subjects, who are unable to provide informed consent for whatever reason, written consent must be obtained from the legal representative, (proxy consent is not permitted in Germany).",
            "criterions": [
                {
                    "exact_snippets": "Written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "form",
                            "expected_value": "written"
                        }
                    ]
                },
                {
                    "exact_snippets": "written consent must be obtained from the legal representative",
                    "criterion": "legal representative consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "form",
                            "expected_value": "written"
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Having received an investigational drug in an investigational trial within 7 half-lives after the last administration of this drug before initiating trial medication, except for subjects entering Part D, who have previously received foscarnet treatment in Part C of this trial.",
            "criterions": [
                {
                    "exact_snippets": "Having received an investigational drug in an investigational trial within 7 half-lives after the last administration of this drug before initiating trial medication",
                    "criterion": "prior investigational drug exposure",
                    "requirements": [
                        {
                            "requirement_type": "time since last investigational drug administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "half-lives"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for subjects entering Part D, who have previously received foscarnet treatment in Part C of this trial",
                    "criterion": "prior foscarnet treatment in Part C (for Part D subjects)",
                    "requirements": [
                        {
                            "requirement_type": "prior foscarnet treatment in Part C",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Having received an investigational drug in an investigational drug trial unter certain conditions.",
            "criterions": [
                {
                    "exact_snippets": "Having received an investigational drug in an investigational drug trial",
                    "criterion": "receipt of investigational drug",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Pregnant and/or breastfeeding women.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding women",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Any other condition which in the opinion of the Investigator would interfere with successful completion of this clinical trial.",
            "criterions": [
                {
                    "exact_snippets": "Any other condition which in the opinion of the Investigator would interfere with successful completion of this clinical trial",
                    "criterion": "other condition interfering with trial completion",
                    "requirements": [
                        {
                            "requirement_type": "investigator opinion of interference",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Subjects will be able to enter Part F only after closure of enrollment in Part D.",
            "criterions": [
                {
                    "exact_snippets": "Subjects will be able to enter Part F only after closure of enrollment in Part D.",
                    "criterion": "enrollment status of Part D",
                    "requirements": [
                        {
                            "requirement_type": "closure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects will be able to enter Part F",
                    "criterion": "entry into Part F",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "In Canada, Germany, Belgium:",
            "criterions": [
                {
                    "exact_snippets": "In Canada, Germany, Belgium:",
                    "criterion": "country of enrollment",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "Canada",
                                "Germany",
                                "Belgium"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Subject, and/or their legally authorized representative, (proxy consent is not permitted in Germany), must be willing and able to understand the Informed Consent Form.",
            "criterions": [
                {
                    "exact_snippets": "Subject, and/or their legally authorized representative, ... must be willing and able to understand the Informed Consent Form.",
                    "criterion": "willingness and ability to understand the Informed Consent Form",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability to understand",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "proxy consent is not permitted in Germany",
                    "criterion": "proxy consent in Germany",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Abnormalities in hematological, clinical chemical or any other laboratory variables.",
            "criterions": [
                {
                    "exact_snippets": "Abnormalities in hematological ... laboratory variables",
                    "criterion": "hematological laboratory variables",
                    "requirements": [
                        {
                            "requirement_type": "abnormality",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Abnormalities in ... clinical chemical ... laboratory variables",
                    "criterion": "clinical chemical laboratory variables",
                    "requirements": [
                        {
                            "requirement_type": "abnormality",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Abnormalities in ... any other laboratory variables",
                    "criterion": "other laboratory variables",
                    "requirements": [
                        {
                            "requirement_type": "abnormality",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "All inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by:",
            "criterions": [
                {
                    "exact_snippets": "All inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by:",
                    "criterion": "inclusion criteria for Part C (except criterion 2)",
                    "requirements": [
                        {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Lesions accessible for visual inspection to allow assessment of lesion healing including visualization by endoscopy.",
            "criterions": [
                {
                    "exact_snippets": "Lesions accessible for visual inspection",
                    "criterion": "lesions",
                    "requirements": [
                        {
                            "requirement_type": "accessibility for visual inspection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "allow assessment of lesion healing including visualization by endoscopy",
                    "criterion": "lesion healing assessment",
                    "requirements": [
                        {
                            "requirement_type": "assessment method",
                            "expected_value": [
                                "visual inspection",
                                "endoscopy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Immunocompromised (due to conditions including but not limited to HIV infection, hematopoietic cell or solid organ transplantation, and chronic use of immunosuppressive treatment) men and women of any ethnic group aged >18 years.",
            "criterions": [
                {
                    "exact_snippets": "Immunocompromised (due to conditions including but not limited to HIV infection, hematopoietic cell or solid organ transplantation, and chronic use of immunosuppressive treatment)",
                    "criterion": "immunocompromised status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "men and women of any ethnic group",
                    "criterion": "sex and ethnicity",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        },
                        {
                            "requirement_type": "ethnicity",
                            "expected_value": "any"
                        }
                    ]
                },
                {
                    "exact_snippets": "aged >18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. ACV-R and foscarnet-R mucocutaneous HSV infection based on clinical failure or positive genotypic/phenotypic resistance testing for current lesion or documented intolerance to iv foscarnet requiring cessation of foscarnet treatment or precluding foscarnet treatment.",
            "criterions": [
                {
                    "exact_snippets": "ACV-R ... mucocutaneous HSV infection",
                    "criterion": "mucocutaneous HSV infection",
                    "requirements": [
                        {
                            "requirement_type": "resistance",
                            "expected_value": "acyclovir-resistant"
                        }
                    ]
                },
                {
                    "exact_snippets": "foscarnet-R mucocutaneous HSV infection",
                    "criterion": "mucocutaneous HSV infection",
                    "requirements": [
                        {
                            "requirement_type": "resistance",
                            "expected_value": "foscarnet-resistant"
                        }
                    ]
                },
                {
                    "exact_snippets": "clinical failure or positive genotypic/phenotypic resistance testing for current lesion",
                    "criterion": "current lesion",
                    "requirements": [
                        {
                            "requirement_type": "clinical failure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "genotypic resistance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "phenotypic resistance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "documented intolerance to iv foscarnet requiring cessation of foscarnet treatment or precluding foscarnet treatment",
                    "criterion": "iv foscarnet intolerance",
                    "requirements": [
                        {
                            "requirement_type": "intolerance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cessation of foscarnet treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "preclusion of foscarnet treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. ACV-R mucocutaneous HSV infection based on clinical failure or positive genotypic/phenotypic ACV resistance testing for current lesion. Clinical failure is defined as no improvement after oral or iv doses for at least 7 days at doses equivalent to or greater than the local agency approved high oral doses of acyclovir, valacyclovir or famciclovir.",
            "criterions": [
                {
                    "exact_snippets": "ACV-R mucocutaneous HSV infection",
                    "criterion": "ACV-resistant mucocutaneous HSV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "based on clinical failure or positive genotypic/phenotypic ACV resistance testing for current lesion",
                    "criterion": "ACV resistance for current lesion",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": [
                                "clinical failure",
                                "positive genotypic ACV resistance testing",
                                "positive phenotypic ACV resistance testing"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinical failure is defined as no improvement after oral or iv doses for at least 7 days at doses equivalent to or greater than the local agency approved high oral doses of acyclovir, valacyclovir or famciclovir.",
                    "criterion": "clinical failure to acyclovir, valacyclovir, or famciclovir",
                    "requirements": [
                        {
                            "requirement_type": "treatment duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "local agency approved high oral dose"
                            }
                        },
                        {
                            "requirement_type": "route",
                            "expected_value": [
                                "oral",
                                "iv"
                            ]
                        },
                        {
                            "requirement_type": "response",
                            "expected_value": "no improvement"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "All exclusion criteria in Part E are identical to those in Part C with the addition of:",
            "criterions": []
        },
        {
            "line": "Part D (complete) exclusion criteria",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}